这是一篇来自已证抗体库的有关人类 RTP801的综述,是根据9篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合RTP801 抗体。
RTP801 同义词: Dig2; REDD-1; REDD1; DNA damage-inducible transcript 4 protein; HIF-1 responsive protein RTP801; protein regulated in development and DNA damage response 1

武汉三鹰
兔 多克隆
  • 免疫印迹; 人类; 图 4a
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹在人类样本上 (图 4a). Nucleic Acids Res (2018) ncbi
兔 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 5h
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5h). Nat Commun (2017) ncbi
兔 多克隆
  • 免疫印迹; 人类; 1:500; 图 1a
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 1a). Sci Rep (2017) ncbi
兔 多克隆
  • 免疫印迹基因敲除验证; 小鼠; 图 2
  • 免疫印迹; 人类; 图 1
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹基因敲除验证在小鼠样本上 (图 2) 和 被用于免疫印迹在人类样本上 (图 1). F1000Res (2016) ncbi
兔 多克隆
  • 免疫印迹; 人类
武汉三鹰 RTP801抗体(Proteintech Group, 10638-1-AP)被用于被用于免疫印迹在人类样本上. Mol Cancer Ther (2015) ncbi
兔 多克隆
  • 免疫印迹; 人类
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
兔 多克隆
  • 免疫印迹; 人类; 图 4a
武汉三鹰 RTP801抗体(Proteintech, 10638-1-AP)被用于被用于免疫印迹在人类样本上 (图 4a). Oncogene (2015) ncbi
兔 多克隆
  • 免疫组化-石蜡切片; 人类; 1:200
  • 免疫印迹; 人类; 1:300
武汉三鹰 RTP801抗体(Proteintech Group, 10638-1-AP)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 和 被用于免疫印迹在人类样本上浓度为1:300. Placenta (2014) ncbi
赛信通(上海)生物试剂有限公司
兔 多克隆
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 RTP801抗体(Cell Signaling Technology, 2516)被用于被用于免疫印迹在人类样本上. Cell Death Differ (2011) ncbi
文章列表
  1. Liu X, Cai S, Zhang C, Liu Z, Luo J, Xing B, et al. Deacetylation of NAT10 by Sirt1 promotes the transition from rRNA biogenesis to autophagy upon energy stress. Nucleic Acids Res. 2018;46:9601-9616 pubmed 出版商
  2. Lee C, Hanna A, Wang H, Dagnino Acosta A, Joshi A, Knoblauch M, et al. A chemical chaperone improves muscle function in mice with a RyR1 mutation. Nat Commun. 2017;8:14659 pubmed 出版商
  3. Salsman J, Stathakis A, Parker E, Chung D, Anthes L, Koskowich K, et al. PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4. Sci Rep. 2017;7:45038 pubmed 出版商
  4. Grainger D, Kutzler L, Rannels S, Kimball S. Validation of a commercially available anti-REDD1 antibody using RNA interference and REDD1-/- mouse embryonic fibroblasts. F1000Res. 2016;5:250 pubmed 出版商
  5. Wang S, Chen X, Hu J, Jiang J, Li Y, Chan Salis K, et al. ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells. Mol Cancer Ther. 2015;14:877-88 pubmed 出版商
  6. Shao C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem. 2015;290:2024-33 pubmed 出版商
  7. Yang C, Matsuura K, Huang N, Robeson A, Huang B, Zhang L, et al. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. Oncogene. 2015;34:3264-72 pubmed 出版商
  8. Wei W, Hu Y. Expression of hypoxia-regulated genes and glycometabolic genes in placenta from patients with intrahepatic cholestasis of pregnancy. Placenta. 2014;35:732-6 pubmed 出版商
  9. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-?Np63? is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18:1220-30 pubmed 出版商